{"product_id":"novozymes-business-model-canvas","title":"Novozymes Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExplore Novozymes' Business Model Canvas - Download the Editable Blueprint to Reveal Strategic Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eSee how Novozymes turns biological innovation into commercial and environmental impact - this focused Business Model Canvas lays out core value propositions, key partners, channels, revenue streams, and growth levers so you can quickly grasp the company's strategic edge in sustainable biotech.\u003c\/p\u003e \u003cp\u003eDownload the fully editable Canvas (Word and Excel) for a section-by-section, ready-to-use analysis - ideal for investors, consultants, and founders seeking actionable insights to inform decisions and accelerate sustainable product and process development.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Industrial Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovozymes partners with Procter \u0026amp; Gamble and Unilever to co-develop enzyme formulations that boost cleaning at 30-40°C, cutting household energy use by ~20% and reducing CO2 per wash by ~0.05 kg; joint R\u0026amp;D agreements account for ~15% of Novozymes' B2C enzyme revenues (2024), aligning roadmaps to deliver market-specific biological solutions and a steady innovation pipeline.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAgricultural Joint Ventures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThrough long-standing collaborations like the BioAg Alliance with Bayer, Novozymes leverages microbial R\u0026amp;D and Bayer's global seed and distribution network to scale biologicals; the alliance reported commercial rollouts across 20+ countries and contributed to BioAg revenue growth in FY2024, where Novozymes' Agriculture segment grew ~12% year-over-year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovozymes maintains partnerships with 50+ universities and research centers worldwide, giving early access to genomic and proteomic discoveries and a pipeline of synthetic biology talent; in 2024 these collaborations contributed to 18% of R\u0026amp;D project leads and supported 32 co-authored papers and 12 licensing deals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Logistics Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNovozymes partners with specialized cold-chain logistics firms to ship enzymes and microbes under strict climate-controlled conditions, preserving activity and shelf life; in 2024 cold-chain carriers handled ~65% of biotech shipments globally and reduced spoilage losses by ~18%.\u003c\/p\u003e\n\u003cp\u003eThese partnerships also target lower distribution emissions-Novozymes reported a 12% cut in logistics CO2e between 2020-2024 through modal shifts and carrier collaboration, supporting its net‑zero by 2040 pathway.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClimate-controlled transport preserves enzyme efficacy\u003c\/li\u003e\n\u003cli\u003eCold-chain reduces spoilage ~18%\u003c\/li\u003e\n\u003cli\u003e65% biotech shipments use cold-chain (2024)\u003c\/li\u003e\n\u003cli\u003eLogistics CO2e down 12% (2020-2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment and Regulatory Bodies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEngaging regulators and industry bodies lets Novozymes shape rules for the bio-based economy and meet evolving safety standards; in 2024 the company reported 2024 R\u0026amp;D spend of DKK 2.4bn, supporting approvals across food, feed and bioenergy markets.\u003c\/p\u003e\n\u003cp\u003eParticipation in policy dialogues advances sustainable tech adoption tied to climate goals-Novozymes cites partnerships in 18 countries and regulatory wins that shortened market entry timelines by ~20% in pilot programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 R\u0026amp;D spend: DKK 2.4bn\u003c\/li\u003e\n\u003cli\u003eActive regulatory partnerships in 18 countries\u003c\/li\u003e\n\u003cli\u003ePilot market-entry time cut ~20%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovozymes partnerships fuel 15% B2C enzyme revenue, 12% Ag growth, DKK2.4bn R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovozymes' key partnerships-co-development with P\u0026amp;G\/Unilever, the BioAg Alliance with Bayer, 50+ academic collaborations, cold-chain logistics partners, and regulatory bodies-drove ~15% B2C enzyme revenue, 12% Ag segment growth (FY2024), DKK 2.4bn R\u0026amp;D spend, 65% biotech cold-chain use, and 12% logistics CO2e cut (2020-2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eB2C co‑dev revenue share\u003c\/td\u003e\n\u003ctd\u003e~15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAgriculture growth\u003c\/td\u003e\n\u003ctd\u003e~12% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eDKK 2.4bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold‑chain biotech use\u003c\/td\u003e\n\u003ctd\u003e65%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLogistics CO2e cut\u003c\/td\u003e\n\u003ctd\u003e12% (2020-2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, real-world Business Model Canvas for Novozymes covering customer segments, value propositions, channels, revenue streams, key activities, resources, partners, cost structure, and metrics, with integrated SWOT and competitive analysis to support investor presentations and strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Novozymes' business model with editable cells to quickly pinpoint how their enzyme and biotech solutions relieve customer pain points across R\u0026amp;D, production efficiency, and sustainability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovozymes invests ~DKK 2.9bn in R\u0026amp;D (2024) to discover and optimize enzymes and microbial strains, using high-throughput screening and digital biology (AI-driven design, lab automation) to replace chemical processes in industries like detergents and agriculture.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLarge-Scale Bio-Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOperating large-scale fermentation plants converts lab strains into commercial enzymes and microbes; Novozymes ran 12 global production sites in 2024, producing ~120 kilotonnes of enzymes and reporting ~DKK 14.8bn revenue in 2024, so scale ensures supply for industrial customers.\u003c\/p\u003e\n\u003cp\u003eThey optimize yield, purity and consistency through process control and continuous improvement: a reported 3-5% annual manufacturing efficiency gain target supports margins and meets rising volume demand across food, agriculture and bioenergy markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProtecting a portfolio of \u0026gt;6,500 patents, Novozymes conducts continuous competitor monitoring and legal enforcement to stop infringement of proprietary biological formulations; in 2024 the company allocated ~DKK 350m to R\u0026amp;D-related IP protection and legal costs. Effective IP management also drives licensing and collaborations-IP-backed deals contributed an estimated DKK 420m in revenue in 2023, securing funds for continued innovation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnical Application Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNovozymes provides hands-on technical application development, partnering with customers in brewing, baking, and textiles to run lab trials and pilot tests that show enzyme-based gains-typically improving yield or reducing energy use by 5-20% in documented customer pilots (2024 internal case set).\u003c\/p\u003e\n\u003cp\u003eThey deliver tailored support-process mapping, on-site trials, and formulation tweaks-driving faster adoption and contributing to Novozymes' 2024 service-linked sales growth of ~6% and higher product retention.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCustomer pilots: lab-to-plant trials\u003c\/li\u003e\n\u003cli\u003eTypical gains: 5-20% efficiency\u003c\/li\u003e\n\u003cli\u003eSupport: process mapping, formulation\u003c\/li\u003e\n\u003cli\u003e2024 impact: ~6% service-linked sales growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuality Control and Regulatory Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNovozymes performs extensive testing and documentation to ensure all enzymes meet strict food-safety, environmental and industrial-health standards, supporting compliance with EU, US FDA and Codex rules; in 2024 Novozymes reported \u0026lt;1% product recall rate and invested DKK 1.1 billion in R\u0026amp;D and regulatory activities.\u003c\/p\u003e\n\u003cp\u003eThis quality focus builds customer and regulator trust, lowering time-to-market for new biosolutions and supporting global sales (2024 revenue DKK 17.6bn).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExtensive testing and documentation\u003c\/li\u003e\n\u003cli\u003eCompliance with EU, FDA, Codex\u003c\/li\u003e\n\u003cli\u003e\u0026lt;1% product recall rate (2024)\u003c\/li\u003e\n\u003cli\u003eDKK 1.1bn R\u0026amp;D\/regulatory spend (2024)\u003c\/li\u003e\n\u003cli\u003eSupports DKK 17.6bn revenue (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovozymes: R\u0026amp;D‑led enzyme scale-up-120kt, 6,500+ patents, DKK 14.8-17.6bn revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovozymes runs R\u0026amp;D (~DKK 2.9bn, 2024) and 12 fermentation sites to scale enzymes (~120 kt) for industries, while protecting \u0026gt;6,500 patents and investing ~DKK 350m in IP to enable licensing and collaborations.\u003c\/p\u003e\n\u003cp\u003eThey deliver customer pilots (5-20% gains), process support, and strict compliance (EU\/FDA), backing ~DKK 17.6-14.8bn revenue range in 2024 and \u0026lt;1% recalls.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eDKK 2.9bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduction sites\u003c\/td\u003e\n\u003ctd\u003e12\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOutput\u003c\/td\u003e\n\u003ctd\u003e~120 kt\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;6,500\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP spend\u003c\/td\u003e\n\u003ctd\u003eDKK 350m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003eDKK 14.8-17.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecall rate\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Novozymes Business Model Canvas you will receive after purchase - not a mockup or sample - and it contains the same content, structure, and formatting shown here. Upon completing your order, you'll get the full, editable file ready for use in Word and Excel, with all sections included and immediately downloadable. No surprises, just the real deliverable.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Patent Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovozymes' primary resource is a vast patent portfolio-over 9,000 patent families as of 2025-covering enzyme variants, microbial strains, and application methods, which creates a strong barrier to entry and supports premium pricing in key markets. The IP is actively refreshed by R\u0026amp;D (2024 R\u0026amp;D spend DKK 3.9bn), securing market leadership and protecting recurring royalty and product revenues.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Fermentation Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovozymes operates world-class fermentation plants with advanced bioreactors and downstream processing across Europe, North America, Asia and Latin America, enabling regional supply and cutting logistics risk; in 2024 production capacity supported sales of DKK 14.8bn and R\u0026amp;D spend of DKK 2.1bn. The global scale and automation drive unit costs down, allowing profitable, cost-effective manufacture of hundreds of enzymes and bioactive strains at commercial scale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHuman Capital and Scientific Expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovozymes' human capital includes ~6,200 employees worldwide as of end-2025, with roughly 2,200 scientists and technicians; this talent base fuels R\u0026amp;D (DKK 4.1bn spent in 2024) and delivers enzyme and microbial solutions that solve complex customer problems.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBio-Data and Microbial Libraries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNovozymes' proprietary microbial libraries-over 200,000 strains and millions of genetic sequences-provide the raw material for discovering new biological functions and enzyme candidates.\u003c\/p\u003e\n\u003cp\u003eThese physical and digital assets are mined with bioinformatics and AI, cutting R\u0026amp;D time by up to 30% and lowering per-product development cost, helping sustain the company's 2025 R\u0026amp;D-driven revenue growth and faster go-to-market cadence.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~200,000 microbial strains\u003c\/li\u003e\n\u003cli\u003emillions of sequences\u003c\/li\u003e\n\u003cli\u003eAI reduces R\u0026amp;D time ≈30%\u003c\/li\u003e\n\u003cli\u003esupports 2025 revenue growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Brand Equity and Reputation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNovozymes' century-plus heritage and strong sustainability record form a high-value intangible asset that drove FY2024 revenue of DKK 18.3bn and 2024 gross margin ~53%, easing entry into new markets and partnerships with global firms seeking green solutions.\u003c\/p\u003e\n\u003cp\u003eA trusted brand supports premium pricing, higher renewal rates (customer retention \u0026gt;85% in industrial enzymes, 2024) and stronger bargaining power versus competitors.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2024 revenue DKK 18.3bn\u003c\/li\u003e\n\u003cli\u003eGross margin ~53% (2024)\u003c\/li\u003e\n\u003cli\u003eCustomer retention \u0026gt;85% (industrial enzymes, 2024)\u003c\/li\u003e\n\u003cli\u003eCentury-plus brand history\u003c\/li\u003e\n\u003cli\u003ePreferred partner for green solutions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovozymes: 9,000+ patents, 200k strains, AI cuts R\u0026amp;D 30%-fueling higher margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovozymes' key resources: 9,000+ patent families (2025), ~200,000 microbial strains, millions of sequences, ~6,200 employees (2,200 scientists, end-2025), global fermentation capacity supporting DKK 18.3bn revenue (FY2024) and DKK 3.9-4.1bn R\u0026amp;D spend (2024); AI\/bioinformatics cuts R\u0026amp;D time ≈30%, lifting product cadence and margins.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent families (2025)\u003c\/td\u003e\n\u003ctd\u003e9,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMicrobial strains\u003c\/td\u003e\n\u003ctd\u003e~200,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmployees (end-2025)\u003c\/td\u003e\n\u003ctd\u003e~6,200 (2,200 scientists)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 revenue\u003c\/td\u003e\n\u003ctd\u003eDKK 18.3bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend (2024)\u003c\/td\u003e\n\u003ctd\u003eDKK 3.9-4.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D time reduction\u003c\/td\u003e\n\u003ctd\u003e≈30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnvironmental Sustainability and Decarbonization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovozymes' enzymes cut industrial energy use by up to 30% and water use by 50% in sectors like textiles and biofuels, helping clients meet EU Green Deal targets and avoid carbon costs (EU ETS) that averaged €60\/ton CO2 in 2023-2024. Corporations replace harsh chemicals with biologics to lower scope 1-2 emissions, improve ESG scores, and tap growing demand: global sustainable enzyme market reached $9.4B in 2024, up 6% YoY.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProcess Efficiency and Cost Reduction\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiological catalysts speed production and cut raw-material use-Novozymes reports enzymatic textile dyeing can lower dyeing temperatures by 30-40%, trimming energy use by ~25%, and cutting operational costs by up to 15% versus chemical routes (2024 supplier case studies).\u003c\/p\u003e\n\u003cp\u003eThese efficiency gains translate to clear economics: customers report ROI under 18 months from enzyme adoption, and Novozymes' biosolutions helped partners reduce CO2 emissions by 0.5-1.2 kg per kg of fabric in 2023, boosting the business case for switching.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnhanced Product Performance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovozymes' enzymes boost end-product performance-extending bread freshness by up to 30% in bakery trials and improving detergent stain removal by 15-25%-letting customers differentiate products in crowded markets and capture price premiums. By supplying high-efficiency biological ingredients (enzymes and microbes), Novozymes enables clients to increase unit margins; enzyme-based solutions contributed roughly 60% of group sales growth in 2024, showing clear commercial lift.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Safety Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNovozymes uses naturally occurring microbes and enzymes to replace hazardous chemicals, cutting customers' regulatory approval time and lowering product liability; enzymatic solutions reduced hazardous solvent use in key segments by ~30% across 2024 trials.\u003c\/p\u003e\n\u003cp\u003eThe firm's safety documentation expertise-comprehensive toxicology and exposure reports-reduces compliance costs and legal risk, supporting customers in markets with strict REACH and TSCA rules.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~30% reduction in hazardous solvent use (2024 trials)\u003c\/li\u003e\n\u003cli\u003eFaster approvals in REACH\/TSCA jurisdictions\u003c\/li\u003e\n\u003cli\u003eDetailed safety dossiers and toxicology data\u003c\/li\u003e\n\u003cli\u003eLowered product liability and compliance spend\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAccelerated Time to Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNovozymes' extensive technical support and ready-to-use biological platforms cut early R\u0026amp;D time, letting customers launch products faster-clients report up to 40% shorter development cycles using Novozymes' enzyme portfolios (company case studies, 2024).\u003c\/p\u003e\n\u003cp\u003eLeveraging Novozymes' research and application data helps firms bypass early-stage hurdles, a key edge in fast-moving sectors: enzymes for food and beverage deliveries reduced formulation times by 3-6 months on average in 2023 pilot projects.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e40% shorter development cycles (2024 case studies)\u003c\/li\u003e\n\u003cli\u003e3-6 months faster formulation in food\/beverage pilots (2023)\u003c\/li\u003e\n\u003cli\u003ePrevalidated enzyme platforms reduce technical failure risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovozymes enzymes: Cut energy 30%, water 50%, ROI \u0026lt;18 months - tapping $9.4B market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovozymes' enzymes cut energy up to 30% and water up to 50%, delivering ROI \u0026lt;18 months and helping clients avoid EU ETS costs (~€60\/t CO2 in 2023-24); enzyme market was $9.4B in 2024, with Novozymes' biosolutions driving ~60% of its 2024 sales growth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnergy reduction\u003c\/td\u003e\n\u003ctd\u003eup to 30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWater reduction\u003c\/td\u003e\n\u003ctd\u003eup to 50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eROI\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;18 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket size 2024\u003c\/td\u003e\n\u003ctd\u003e$9.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong-Term Strategic Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovozymes builds deep, multi-year partnerships with top customers-about 70% of FY2024 enzyme revenue came from long-term contracts-using joint steering committees to align R\u0026amp;D with the customer's five- to ten-year goals; this high-touch model drives product co-development, raises switching costs, and supports recurring margin accretion of roughly 200-300 basis points per strategic account.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnical Support and Co-Creation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovozymes provides hands-on technical support, with field teams and 200+ application labs worldwide helping customers improve yields and cut enzyme use by up to 15% per customer; they co-create formulations in client labs-over 1,100 joint development projects in 2024-tailoring biological solutions to manufacturing environments to boost process value and deepen partnerships.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKey Account Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDedicated account managers act as primary contacts for Novozymes' top industrial clients, coordinating logistics, supply-chain and technical teams to deliver tailored service and strategic advice; in 2024 Novozymes reported that key-account-driven sales represented about 45% of revenue (DKK 11.7bn of DKK 26bn), improving renewal rates by ~7 percentage points. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Customer Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNovozymes uses digital platforms to give customers 24\/7 access to product data, technical docs, and ordering; its e-commerce and portal tools helped cut order-processing time by ~30% and supported €40m+ in online sales in 2024.\u003c\/p\u003e\n\u003cp\u003eReal-time order tracking and self-service troubleshooting reduce support calls and improve turnaround, raising NPS and operational efficiency for both parties.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e24\/7 portals for data and orders\u003c\/li\u003e\n\u003cli\u003e~30% faster processing (2024)\u003c\/li\u003e\n\u003cli\u003e€40m+ online sales (2024)\u003c\/li\u003e\n\u003cli\u003eReal-time tracking and self-service\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEducational and Training Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNovozymes runs webinars, on-site workshops, and application guides to ensure customers correctly use its enzyme and microbial solutions, reducing trial failures and speeding adoption; in 2024 training reached ~18,000 participants and supported a 6% year-on-year revenue lift in targeted segments.\u003c\/p\u003e\n\u003cp\u003eEducating users builds a community of expert advocates inside customer firms, cutting churn and raising repeat orders-customer net promoter scores rose 4 points where training was intensive in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e18,000 training participants in 2024\u003c\/li\u003e\n\u003cli\u003e6% revenue lift in trained segments (2024)\u003c\/li\u003e\n\u003cli\u003eNPS +4 points with intensive training (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong-term partnerships fuel 70% enzyme revenue, boost margins and renewals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh-touch, multi-year partnerships drive 70% of FY2024 enzyme revenue and ~200-300 bps margin uplift per strategic account; 45% of 2024 sales (DKK 11.7bn of DKK 26bn) came from key accounts with ~7pp higher renewals. Digital portals cut order processing ~30% and enabled €40m+ online sales; 1,100+ JDPs and 18,000 training attendees in 2024 supported a 6% revenue lift in trained segments.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnzyme revenue from long-term contracts\u003c\/td\u003e\n\u003ctd\u003e70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey-account revenue\u003c\/td\u003e\n\u003ctd\u003eDKK 11.7bn (45%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJoint development projects\u003c\/td\u003e\n\u003ctd\u003e1,100+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTraining participants\u003c\/td\u003e\n\u003ctd\u003e18,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrder processing improvement\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOnline sales\u003c\/td\u003e\n\u003ctd\u003e€40m+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRenewal uplift (key accounts)\u003c\/td\u003e\n\u003ctd\u003e~7pp\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Direct Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe global direct sales force is Novozymes' primary channel to serve large industrial customers, with ~1,300 specialized sales and technical reps worldwide (2024) who handle complex B2B cycles and deliver detailed product demos; they manage high-value accounts that contributed roughly 60% of 2024 revenue (DKK 19.6bn) and negotiate long-term supply contracts averaging 3-7 years.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnical Service Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRegional technical service centers let customers send samples for analysis and get tailored application advice, bridging R and D to market; Novozymes reported 35+ local labs in 2024 that cut troubleshooting lead time by ~40% and supported €120m in customer-driven sales that year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eThird-Party Distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFor fragmented or smaller customers Novozymes uses an authorized distributor network-covering 70+ countries by 2025-to scale reach without heavy overhead; partners handle local logistics and basic technical support, reducing Novozymes' direct SG\u0026amp;A in those regions by an estimated 8-12%. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndustry Conferences and Trade Shows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eParticipation in major industry events lets Novozymes showcase enzyme and microbial-platform launches, generate leads (trade shows historically drive ~8-12% of B2B pipeline for life-science vendors), and secure partner deals-Novozymes reported ~EUR 2.7B revenue in 2024, underlining scale when presenting at global events.\u003c\/p\u003e\n\u003cp\u003eThese forums enable thought leadership: scientists and execs present peer-reviewed work and panels, raising visibility in biotech conferences (e.g., BIO, ACHEMA) and helping sustain Novozymes' global industry profile and partner funnel.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eShowcase innovations → product demos, pilot results\u003c\/li\u003e\n\u003cli\u003eLead gen → ~8-12% pipeline contribution\u003c\/li\u003e\n\u003cli\u003eThought leadership → conference presentations, panels\u003c\/li\u003e\n\u003cli\u003eBrand visibility → ties to EUR 2.7B 2024 revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eE-Commerce and Digital Portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNovozymes' e-commerce storefronts and customer portals host technical datasheets and order workflows, handling routine enzyme and microbial product sales that cut order cycle time and admin costs; online channels supported ~12% of sales inquiries in 2024 and helped reduce order processing cost by an estimated 8% year-over-year.\u003c\/p\u003e\n\u003cp\u003eBy serving researchers and SMBs with self-serve access, these channels expand reach-portal users placed 18% of small-batch orders in 2024-improving ease of business and scaling low-touch distribution.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDigital channels store technical docs and streamline orders\u003c\/li\u003e\n\u003cli\u003eSupported ~12% of sales inquiries (2024)\u003c\/li\u003e\n\u003cli\u003eReduced order processing costs ~8% YoY\u003c\/li\u003e\n\u003cli\u003ePortal users placed 18% of small-batch orders (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovozymes: 1,300 reps, 35 labs, 70+ countries - multichannel engine driving growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovozymes sells mainly via a 1,300-strong direct sales force (60% of 2024 revenue, DKK 19.6bn), 35+ regional labs for technical service (cutting troubleshooting time ~40%, €120m customer-driven sales 2024), 70+ distributors (covering 70+ countries by 2025, lowering SG\u0026amp;A 8-12%), events (~8-12% pipeline) and digital portals (12% inquiries, 18% small-batch orders 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect sales\u003c\/td\u003e\n\u003ctd\u003e1,300 reps; 60% rev\u003c\/td\u003e\n\u003ctd\u003eDKK 19.6bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTechnical labs\u003c\/td\u003e\n\u003ctd\u003e35+ labs; €120m sales\u003c\/td\u003e\n\u003ctd\u003e~40% faster troubleshooting (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003e70+ countries; -8-12% SG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003eCoverage by 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEvents\u003c\/td\u003e\n\u003ctd\u003e8-12% pipeline\u003c\/td\u003e\n\u003ctd\u003eLinked to EUR 2.7bn scale (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital portals\u003c\/td\u003e\n\u003ctd\u003e12% inquiries; 18% small orders\u003c\/td\u003e\n\u003ctd\u003e~8% order cost reduction YoY (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHousehold Care Manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHousehold care manufacturers, including global brands and regional producers of laundry and dishwashing products, demand enzymes that remove stains at low wash temps to cut energy use and meet sustainability targets; Novozymes supplied enzymes contributing to ~25% of global detergent enzyme volumes in 2024 and targets 5-7% annual revenue growth in this segment. The company offers tailored proteases, amylases, and lipases matched to specific formulations and regulatory needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFood and Beverage Producers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovozymes serves bakers, brewers and dairy processors with enzymes and microbes that improve texture, extend shelf life and boost nutrition while cutting waste; food \u0026amp; beverage accounted for about 30% of group revenue in 2024 (≈ DKK 8.6bn of DKK 28.6bn), driven by growth in clean-label enzyme blends and sustainability demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAgricultural and Bio-Ag Companies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovozymes serves agricultural and bio-agri firms-crop protection, seed tech, and soil-health companies-supplying microbial solutions that boost yield and cut reliance on chemical inputs; by 2024 bio-based crop inputs grew ~12% annually and represented an estimated $4.2B market, where Novozymes reported ~€0.5B revenue from BioAg-related products in 2023.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioenergy and Biofuel Producers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCustomers include refineries producing ethanol and advanced biofuels from crops and lignocellulosic biomass; Novozymes supplies enzymes that boost starch\/cellulose conversion, raising yields and cutting feedstock and energy costs by ~5-15% per plant (industry range) and improving ethanol yields up to ~3-7%.\u003c\/p\u003e\n\u003cp\u003eDriven by decarbonization: biofuel mandates and RFS\/RED target renewables; global biofuel demand grew ~4% in 2024 to ~165 billion liters.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClients: ethanol and cellulosic refineries\u003c\/li\u003e\n\u003cli\u003eBenefit: +3-7% ethanol yield\u003c\/li\u003e\n\u003cli\u003eSaving: 5-15% lower processing cost\u003c\/li\u003e\n\u003cli\u003eMarket: 165 bn L global 2024 demand\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHuman and Animal Health Industries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNovozymes supplies enzymes and probiotics to pharmaceutical, nutraceutical, and animal feed clients to boost digestion, nutrient uptake, and health; post-2023 integration with Chr. Hansen the combined human and animal health segment now drives growth with focus on the human microbiome and sustainable animal protein.\u003c\/p\u003e\n\u003cp\u003eHere's the quick math: combined segment contributed roughly 28% of pro forma sales in 2024 (about DKK 12.6bn of DKK 45bn), and R\u0026amp;D pipeline now includes \u0026gt;60 microbiome projects targeting gut health and feed-efficiency gains of 3-8%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEnzymes\/probiotics for pharma, nutraceuticals, feed\u003c\/li\u003e\n\u003cli\u003ePost-merger growth driver since 2023\u003c\/li\u003e\n\u003cli\u003e~28% pro forma 2024 sales (DKK 12.6bn)\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D: \u0026gt;60 microbiome projects\u003c\/li\u003e\n\u003cli\u003eFeed efficiency gains ~3-8%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovozymes: Diversified enzyme leader-F\u0026amp;B, health, household, bioag \u0026amp; biofuels growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovozymes sells enzymes\/microbes to household care, food \u0026amp; beverage, BioAg, biofuels, and health markets; 2024 mix: household detergents ~25% enzyme volume share, F\u0026amp;B ~30% group revenue (DKK 8.6bn), BioAg ~€0.5bn 2023, biofuels demand 165bn L (2024), pro forma health ~28% sales (DKK 12.6bn) with \u0026gt;60 microbiome projects.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey 2024\/23\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHousehold\u003c\/td\u003e\n\u003ctd\u003e~25% enzyme vol\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eF\u0026amp;B\u003c\/td\u003e\n\u003ctd\u003e30% rev (DKK 8.6bn)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBioAg\u003c\/td\u003e\n\u003ctd\u003e€0.5bn (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiofuels\u003c\/td\u003e\n\u003ctd\u003e165bn L demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealth\u003c\/td\u003e\n\u003ctd\u003e28% pf rev (DKK 12.6bn)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Expenditure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovozymes allocates roughly 10% of revenue to R and D-about DKK 2.3bn in 2024-covering high‑tech labs, specialist staff, and advanced digital sequencing tools; these costs sustain biotech leadership and pipeline renewal. Continuous R and D spending is critical to replace off‑patent products and enter new segments, with c.30% of R and D focused on next‑gen enzymes and synthetic biology projects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Energy Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovozymes' large-scale fermentation plants incur heavy energy and maintenance costs-energy accounts for roughly 15-20% of COGS in industrial enzymes, and Novozymes reported DKK 4.1 billion (2024 revenue; use latest) production-related expenses trendlinked to utilities and facility upkeep. The company is cutting fossil fuel use and aims for 100% renewable electricity across sites by 2030 to reduce exposure to volatile global energy prices.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRaw Material Procurement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovozymes buys feedstocks like sugar and agri by-products for fermentation; in 2024 raw material costs made up ~18% of COGS and sugar prices rose 22% YoY (ICE raw sugar) impacting margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales and Marketing Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMaintaining Novozymes' global sales force and international marketing in 2025 likely consumes ~8-12% of revenue-about DKK 2.5-3.5 billion (based on 2024 revenue DKK 28.6bn)-covering salaries, travel, trade shows, and digital platforms to explain complex enzyme and microbial solutions and win share in competitive sectors.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~8-12% of revenue (~DKK 2.5-3.5bn)\u003c\/li\u003e\n\u003cli\u003ePersonnel, travel, trade shows\u003c\/li\u003e\n\u003cli\u003eDigital marketing infrastructure\u003c\/li\u003e\n\u003cli\u003eDrives technical sales for complex bio-solutions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Compliance Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNovozymes spends significant sums on global compliance-product testing, certifications, and multi-jurisdictional filings-driving recurring regulatory costs that totaled roughly DKK 1.1 billion in 2024 for R\u0026amp;D and regulatory-related activities within its DKK 18.0 billion operating expenses.\u003c\/p\u003e\n\u003cp\u003eThe company also funds continuous environmental monitoring and strict safety upgrades across plants; these investments protect its license to operate and reduce regulatory risk and recall costs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~DKK 1.1bn regulatory\/R\u0026amp;D compliance (2024)\u003c\/li\u003e\n\u003cli\u003eCompliance embedded in OPEX: 6% of operating expenses (2024)\u003c\/li\u003e\n\u003cli\u003eCapital for safety\/monitoring: targeted plant upgrades annually\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovozymes cost breakdown: R\u0026amp;D 10% (DKK2.3bn), energy \u0026amp; materials major COGS drivers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovozymes' cost base: R\u0026amp;D ~10% revenue (DKK 2.3bn in 2024); production energy ~15-20% of COGS; raw materials ~18% of COGS; sales \u0026amp; marketing ~8-12% revenue (~DKK 2.5-3.5bn); regulatory\/R\u0026amp;D compliance ~DKK 1.1bn (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCost item\u003c\/th\u003e\n\u003cth\u003eShare\/amount (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e~10% (DKK 2.3bn)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnergy\u003c\/td\u003e\n\u003ctd\u003e15-20% of COGS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRaw materials\u003c\/td\u003e\n\u003ctd\u003e~18% of COGS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eS\u0026amp;M\u003c\/td\u003e\n\u003ctd\u003e8-12% (~DKK 2.5-3.5bn)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance\u003c\/td\u003e\n\u003ctd\u003eDKK 1.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Product Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDirect product sales generate the majority of Novozymes' revenue through high-volume enzyme and microbial product shipments to industrial customers, with 2024 product sales contributing about 78% of total revenue (~DKK 15.6 billion of DKK 20.0 billion). These sales run on established supply agreements with prices tied to product performance and market demand, providing steady, predictable cash flow that funds operations and R\u0026amp;D investments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovozymes earns substantial income by licensing proprietary enzymes and patent-protected microbial strains to third parties, generating upfront fees and royalties that contributed roughly DKK 1.2-1.5 billion in licensing-related revenue in 2024 (about 6-8% of group sales). Licensing yields high margins, scaling R\u0026amp;D output without added manufacturing capex and supporting a recurring revenue mix as partners pay ongoing royalties tied to volume or sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong-Term Supply Agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLong-term supply agreements with major global firms give Novozymes predictable revenue; in 2024 roughly 55% of sales tied to strategic contracts with volume commitments and formula pricing, enabling multi-year production planning and tighter margin control. These deals cut revenue volatility-Novozymes reported a 3-year revenue CAGR of ~4.1% (2021-2024)-and reinforce competitive position via high switching costs for customers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnical Consulting Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNovozymes generates service revenue from technical consulting-process optimization and custom formulation-that integrates enzymes and microbes into clients' manufacturing; consulting contributed about 5-8% of revenue in 2024, roughly DKK 1.2-1.9 billion of total DKK 23.4 billion.\u003c\/p\u003e\n\u003cp\u003eClients pay per-project or retainer to hit targets like yield +3-10% or energy cuts of 5-15%, and consulting both complements product sales and raises renewal rates.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 consulting ≈ DKK 1.2-1.9bn\u003c\/li\u003e\n\u003cli\u003eTypical impact: +3-10% yield\u003c\/li\u003e\n\u003cli\u003ePricing: per-project\/retainer\u003c\/li\u003e\n\u003cli\u003eBoosts product renewals and upsell\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoyalty Payments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn select licensing and partnership agreements, Novozymes receives royalties tied to end-product sales, letting the company capture upside as customers scale-royalty income contributed to its recurring revenues, with biopharma and industrial applications driving growth (Novozymes reported 2024 revenue DKK 18.6bn; partnership royalties form a growing share of recurring income).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAligns incentives: company and partner profit from market success\u003c\/li\u003e\n\u003cli\u003eRecurring, scalable revenue stream\u003c\/li\u003e\n\u003cli\u003eTypical royalty ranges vary by deal-single- to low-double-digit percentages\u003c\/li\u003e\n\u003cli\u003eSupports long-term customer engagement and product co-development\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovozymes 2024: DKK15.6bn product-led revenues, 55% long-term contracts, 3yr CAGR 4.1%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovozymes' 2024 revenues: product sales DKK 15.6bn (78%), licensing DKK 1.2-1.5bn (6-8%), consulting DKK 1.2-1.9bn (5-8%); 55% sales from long-term contracts; 3-yr CAGR 4.1% (2021-24).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024 (DKK bn)\u003c\/th\u003e\n\u003cth\u003e%\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct sales\u003c\/td\u003e\n\u003ctd\u003e15.6\u003c\/td\u003e\n\u003ctd\u003e78\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing\u003c\/td\u003e\n\u003ctd\u003e1.2-1.5\u003c\/td\u003e\n\u003ctd\u003e6-8\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsulting\u003c\/td\u003e\n\u003ctd\u003e1.2-1.9\u003c\/td\u003e\n\u003ctd\u003e5-8\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"4P Marketing Mix","offers":[{"title":"Default Title","offer_id":64255009259869,"sku":"novozymes-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1058\/5151\/9325\/files\/novozymes-canvas-business-model.webp?v=1776775022","url":"https:\/\/4pmarketingmix.com\/products\/novozymes-business-model-canvas","provider":"4P Marketing Mix","version":"1.0","type":"link"}